Semaglutide biosimilar(ChongQing chenan biopharmaceutical)

司美格鲁肽生物类似药（重庆宸安生物）

Report date: 2024/07/10 10:37:26

Base Information

Drug NameSemaglutide biosimilar(ChongQing chenan biopharmaceutical)
Drug Alias Namesemaglutida索马鲁肽semaglutidum索玛鲁肽司美鲁肽 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChongqing Chenan Biopharmaceutical Co LtdShanghai Bovax Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Bovax Biotechnology Co LtdChongqing Chenan Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG